Artificial Intelligence
BioXcel Therapeutics Announces Initiation of a Phase 2 Study Designed to Assess Agitation-Associated Biomarkers and their Response to BXCL501
Study aims to support BXCL501’s potential market expansion in chronic agitation disease conditions
Topline results expected in the second quarter of 2020NEW HAVEN, Conn., Feb. 18, 2020 (GLOBE NEWSWIRE) — BioXcel Therapeutics, Inc. (“BTI” or “Company”) (Nasdaq: BTAI), a clinical-stage biopharmaceutical company utilizing artificial intelligence approaches to identify and advance the next wave of medicines in neuroscience and immuno-oncology, today announced the initiation of a Phase 2 study by researchers at Yale University designed to measure biomarkers associated with agitation in patients with schizophrenia and the response to treatment with BXCL501. The Company aims to utilize biomarkers to identify additional indications that exhibit the same physiological signals of hyperarousal, expanding the potential use of BXCL501 to new chronic disease indications.“Building on the significant results from our Phase 1b trial in patients with agitation associated with schizophrenia, this study is designed to further confirm the calming capabilities of dexmedetomidine, the active ingredient in BXCL501, using an objective scale to measure signs of hyperarousal,” commented Dr. Frank Yocca, Chief Scientific Officer of BTI. “In an agitated state, there are physiological changes that may occur, including differences in heart rate, electrodermal activity and EEG (electroencephalography), which have the potential to be used as an initial signal for treatment with BXCL501. In addition, we believe these biomarkers may have relevance for the treatment of additional distinct chronic indications characterized by nervous system arousal, including Post-Traumatic Stress Disorder and alcohol withdrawal symptoms.”“Managing agitation, a common symptom of neuropsychiatric conditions, is a burdensome challenge for both physicians and caregivers,” added Dr. John Krystal, M.D., Robert L. McNeil, Jr. Professor of Translational Research and Professor of Psychiatry and of Neuroscience; Co-Director, Yale Center for Clinical Investigation and Chair, Department of Psychiatry at Yale School of Medicine. “The ability to detect bodily signals that indicate an agitated state prior to the onset of visible symptoms could be extremely beneficial to caregivers. An early signal will allow for sufficient time to proactively treat the agitation before it becomes dangerous to the individuals involved.”The study will assess biomarkers, such as heart rate variability, actigraphy, electrodermal activity and EEG in patients with schizophrenia. Measurements will be taken at baseline and after the dosing of BXCL501 to determine its ability to impact the physiological signals of agitation. Topline data is expected to be reported in the second quarter of 2020.About BXCL501
BXCL501 is a potential first-in-class, proprietary sublingual thin film of dexmedetomidine, a selective alpha-2a receptor agonist for the treatment of acute agitation. BTI believes that BXCL501 directly targets a causal agitation mechanism and the Company has observed anti-agitation effects in multiple clinical studies across multiple neuropsychiatric indications. BXCL501 has also been granted Fast Track Designation by the U.S. Food and Drug Administration for the acute treatment of agitation.A Phase 1b safety and efficacy study of BXCL501 yielded positive dose-response data. BXCL501 is being evaluated in the SERENITY program, consisting of two Phase 3 studies for the acute treatment of agitation in patients with schizophrenia (SERENITY I) and bipolar disorder (SERENITY II). BXCL501 is also being evaluated in a Phase 1b/2 trial for the treatment of agitation associated with dementia, and the Company is preparing to initiate the Phase 1b/2 RELEASE trial of BXCL501 for the treatment of opioid withdrawal symptoms.About BioXcel Therapeutics, Inc.
BioXcel Therapeutics, Inc. is a clinical stage biopharmaceutical company utilizing artificial intelligence to identify improved therapies in neuroscience and immuno-oncology. BTI’s drug re-innovation approach leverages existing approved drugs and/or clinically validated product candidates together with big data and proprietary machine learning algorithms to identify new therapeutic indices. BTI’s two most advanced clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neuropsychiatric disorders, and BXCL701, an orally administered systemic innate immunity activator designed for treatment of a rare form of prostate cancer, pancreatic cancer and advanced solid cancers in combination with other immuno-oncology agents. For more information, please visit http://www.bioxceltherapeutics.com/.Forward-Looking Statements
This press release includes “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements in this press release include but are not limited to the ability to assess biomarkers for agitation and the timing of data from such trials involving BXCL501. When used herein, words including “anticipate,” “being,” “will,” “plan,” “may,” “continue,” and similar expressions are intended to identify forward-looking statements. In addition, any statements or information that refer to expectations, beliefs, plans, projections, objectives, performance or other characterizations of future events or circumstances, including any underlying assumptions, are forward-looking. All forward-looking statements are based upon BTI’s current expectations and various assumptions. BTI believes there is a reasonable basis for its expectations and beliefs, but they are inherently uncertain. BTI may not realize its expectations, and its beliefs may not prove correct. Actual results could differ materially from those described or implied by such forward-looking statements as a result of various important factors, including, without limitation, its limited operating history; its incurrence of significant losses; its need for substantial additional funding and ability to raise capital when needed; its limited experience in drug discovery and drug development; its dependence on the success and commercialization of BXCL501 and BXCL701 and other product candidates; the failure of preliminary data from its clinical studies to predict final study results; failure of its early clinical studies or preclinical studies to predict future clinical studies; its ability to receive regulatory approval for its product candidates; its ability to enroll patients in its clinical trials; its approach to the discovery and development of product candidates based on EvolverAI is novel and unproven; its exposure to patent infringement lawsuits; its ability to comply with the extensive regulations applicable to it; its ability to commercialize its product candidates; and the other important factors discussed under the caption “Risk Factors” in its Quarterly Report on Form 10-Q for the quarterly period ended September 30, 2019, as such factors may be updated from time to time in its other filings with the SEC, which are accessible on the SEC’s website at www.sec.gov and on the Company’s website at www.bioxceltherapeutics.com.These and other important factors could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management’s estimates as of the date of this press release. While BTI may elect to update such forward-looking statements at some point in the future, except as required by law, it disclaims any obligation to do so, even if subsequent events cause our views to change. These forward-looking statements should not be relied upon as representing BTI’s views as of any date subsequent to the date of this press release.BioXcel Therapeutics, Inc.
www.bioxceltherapeutics.comInvestor Relations:
John Graziano
[email protected]
1.646.378.2942Media:
Julia Deutsch
[email protected]
1.646.378.2967Source: BioXcel Therapeutics, Inc.
Artificial Intelligence
Digital Healthcare Market Size to reach $836.10 billion by 2031, growing at a CAGR of 21%, says Coherent Market Insights
BURLINGAME, Calif., July 4, 2024 /PRNewswire/ — The global Digital Healthcare Market, valued at $220.10 billion in 2024, is on a trajectory of rapid expansion, with projections indicating it will soar to $836.10 billion by 2031, growing at a compound annual growth rate (CAGR) of 21% from 2024 to 2031, as per a recent report by Coherent Market Insights. Various healthcare organizations have started implementing telehealth solutions to provide care to patients from remote locations and reduce disease exposure in clinical settings. Telehealth is enabling virtual doctor consultations, remote monitoring of chronic conditions, and digital communication between healthcare providers and patients. The convenience of accessing healthcare services digitally without visiting clinics physically is driving more patients and providers to adopt telehealth. This increased adoption of telehealth is expected to propel the growth of the overall digital healthcare market in the coming years.
Request Sample Report: https://www.coherentmarketinsights.com/insight/request-sample/4623
Market Dynamics:
The growth of digital healthcare market is driven by increasing adoption of telehealth and telemedicine. Telehealth allows remote consultation for the healthcare providers and patients which increases the convenience of treatment. During COVID-19 pandemic, telehealth witnessed exponential growth as it addressed the challenge of physical distancing. Moreover, growing usage of smartphones and tablets has fueled the demand for various healthcare apps for self-diagnosis and monitoring of chronic conditions. These apps provide healthcare services at affordable costs compared to regular hospital visits.
Digital Healthcare Market Report Coverage
Report Coverage
Details
Market Revenue in 2024
$220.10 billion
Estimated Value by 2031
$836.10 billion
Growth Rate
Poised to grow at a CAGR of 21%
Historical Data
2019–2023
Forecast Period
2024–2031
Forecast Units
Value (USD Million/Billion)
Report Coverage
Revenue Forecast, Competitive Landscape, Growth Factors, and Trends
Segments Covered
By Technology, By Component, By End User
Geographies Covered
North America, Europe, Asia Pacific, and Rest of World
Growth Drivers
Aging Population and Need for Remote Patient Monitoring Launch of new products
Restraints & Challenges
Data security and privacy concern Lack of digital infrastructure in developing regions
Market Trends:
Growing Trend of Remote Patient Monitoring: Remote patient monitoring allows continuous tracking of vital signs outside of conventional clinical settings which improves patient engagement. It ensures safety of high risk patients such as ones with chronic illnesses by alerting healthcare providers in case of any emergencies.
Growing Trend of Digital Therapeutics: Digital therapeutics deliver evidence-based therapeutic interventions to patients that are driven by high quality software programs to prevent, manage, or treat a medical disorder or disease. They are used to effectively treat various medical conditions such as diabetes, insomnia, chronic pain etc. with minimal physical interaction.
Immediate Delivery Available | Buy This Premium Research Report: https://www.coherentmarketinsights.com/insight/buy-now/4623
Market Opportunities:
Healthcare analytics segment accounts for more than 30% share of the overall digital healthcare market. Healthcare analytics solutions help in population health management, clinical variability reduction, financial performance and many other applications. It provides actionable insights from large amounts of medical data for better clinical and financial outcomes.
mHealth segment is growing rapidly, driven by increasing penetration of smartphones and tablets. mHealth apps and solutions enable remote monitoring of patients, medical personnel connectivity, delivery of healthcare services and information. They improve access and convenience of care while reducing costs.
Key Market Takeaways:
The global digital healthcare market is anticipated to witness a CAGR of 21% during the forecast period 2024-2031, owing to growing investments and initiatives in digital transformation of healthcare systems.
On the basis of technology, healthcare analytics segment is expected to hold a dominant position, accounting for over 30% market share due to improved quality of care and medical outcomes with data-driven insights.
By component, software segment dominates with around 60% share owing to various healthcare IT solutions for electronic health records, revenue cycle management, practice management and others.
Regionally, North America is expected to hold a dominant position over the forecast period, with over 35% share of the global market due to advanced digital healthcare infrastructure and favorable government policies in the region.
Key players operating in the digital healthcare market include Telefonica S.S., Epic Systems Corporation, AT&T, AirStrip Technologies, Google, Inc., Hims & Hers Health Inc., Orange, Softserve, Computer Programs and Systems, Inc., Vocera Communication, IBM Corporation, CISCO System, Inc. Apple Inc., Oracle Cerner Veradigm, and Mckesson Corporation among others. Strategic partnerships for product development and geographical expansion are leveraged by these players.
Recent Developments:
In January 2024, Eli Lilly and Company, introduced LillyDirect, a novel digital healthcare solution for patients in the U.S. dealing with obesity, migraine, and diabetes.
In March 2023, BlueRock Therapeutics LP, announced a partnership with Emerald innovations and Rune Labs, health analytics company focusing on leveraging contract less and invisible wearable digital health technology, to enhance monitoring for Parkinson;s disease.
Request For Customization: https://www.coherentmarketinsights.com/insight/request-customization/4623
Detailed Segmentation-
By Technology:
Healthcare AnalyticsmHealthTele-healthOthersBy Component:
SoftwareHardwareServicesBy End User:
Hospital & ClinicsPatientsProvidersPayersOthersBy Region:
North America:
U.S.CanadaLatin America:
BrazilArgentinaMexicoRest of Latin AmericaEurope:
GermanyU.K.SpainFranceItalyRussiaRest of EuropeAsia Pacific:
ChinaIndiaJapanAustraliaSouth KoreaASEANRest of Asia PacificMiddle East:
GCC CountriesIsraelRest of Middle EastAfrica:
South AfricaNorth AfricaCentral AfricaBrowse More Trending Reports:
Global Telehealth Services Market: The global telehealth services market was valued at US$ 12.47 Bn in 2023 and is expected to reach US$ 26.64 Bn by 2031, growing at a compound annual growth rate (CAGR) of 10.2% from 2024 to 2031.
Healthcare API Market: The healthcare API market is estimated to be valued at USD 228.3 Mn in 2024 and is expected to reach USD 345.5 Mn by 2031, exhibiting a compound annual growth rate (CAGR) of 6.1% from 2024 to 2031.
Global Well Being Platform Market: The global well being platform market size is expected to reach US$ 87.38 Bn by 2030, from US$ 62.93 Bn in 2023, exhibiting a compound annual growth rate (CAGR) of 4.8% during the forecast period.
Healthcare Consulting Services Market: The global healthcare consulting services market is estimated to be valued at USD 30.53 Bn in 2024 and is expected to reach USD 57.49 Bn by 2031, exhibiting a compound annual growth rate (CAGR) of 9.5% from 2024 to 2031.
About Us:
Coherent Market Insights is a global market intelligence and consulting organization that provides syndicated research reports, customized research reports, and consulting services. We are known for our actionable insights and authentic reports in various domains including aerospace and defense, agriculture, food and beverages, automotive, chemicals and materials, and virtually all domains and an exhaustive list of sub-domains under the sun. We create value for clients through our highly reliable and accurate reports. We are also committed in playing a leading role in offering insights in various sectors post-COVID-19 and continue to deliver measurable, sustainable results for our clients.
Contact Us:Mr. ShahSenior Client Partner – Business DevelopmentCoherent Market InsightsPhone: US: +1-206-701-6702UK: +44-020-8133-4027Japan: +81-050-5539-1737India: +91-848-285-0837Email: [email protected] Website: https://www.coherentmarketinsights.comFollow Us: LinkedIn | Twitter
Photo: https://mma.prnewswire.com/media/2454252/Digital_Healthcare_Market.jpgLogo: https://mma.prnewswire.com/media/902389/Coherent_Market_Insights_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/digital-healthcare-market-size-to-reach-836-10-billion-by-2031–growing-at-a-cagr-of-21-says-coherent-market-insights-302189503.html
LINKÖPING, Sweden, July 4, 2024 /PRNewswire/ — Medical imaging IT and cybersecurity company Sectra (STO: SECT B) is publishing its Annual Report and Sustainability Report for the 2023/2024 fiscal year today. This report also includes the Corporate Governance Report for the same period.
The documents are attached to this press release and are also available on Sectra’s website, investor.sectra.com.
A summary of the financial year is also available on the website. The 2023/2024 financial year in brief summarizes the value we create for various stakeholders, highlights from our operations, and a selection of financial performance measures.
This information constitutes information that Sectra AB (publ) is obliged to make public pursuant to the Swedish Securities Markets Act. The information was submitted for publication, through the agency of the contact person set out below, at 10:45 a.m. (CEST) on July 4, 2024.
About SectraSectra contributes to a healthier and safer society by assisting health systems throughout the world to enhance the efficiency of care, and authorities and defense forces in Europe to protect society’s most sensitive information. The company, founded in 1978, is headquartered in Linköping, Sweden, with direct sales in 19 countries, and distribution partners worldwide. Sales in the 2023/2024 fiscal year totaled SEK 2,964 million. The Sectra share is quoted on the Nasdaq Stockholm exchange. For more information, visit Sectra’s website.
For further information, please contact:Dr. Torbjörn Kronander, President and CEO, Sectra AB, +46 (0) 705 23 52 27
This information was brought to you by Cision http://news.cision.com.
https://news.cision.com/sectra/r/sectra-publishes-annual-report-and-sustainability-report-for-2023-2024,c4009524
The following files are available for download:
https://mb.cision.com/Main/1263/4009524/2900457.pdf
Sectra Annual Report and Sustainability Report 2023/2024
https://mb.cision.com/Main/1263/4009524/2901565.zip
sectra-2024-04-30-sv.zip
https://news.cision.com/sectra/i/sectra-s-annual-report-and-sustainability-report-2023-2024,c3316505
Sectra’s Annual Report and Sustainability Report 2023/2024
https://news.cision.com/sectra/i/sectra-s-annual-report-and-sustainability-report-2023-2024,c3317128
Sectra’s Annual Report and Sustainability Report 2023/2024
View original content:https://www.prnewswire.co.uk/news-releases/sectra-publishes-annual-report-and-sustainability-report-for-20232024-302189526.html
Artificial Intelligence
Delvitech and Eurotech: a partnership to take quality control to the next level
From Mathematical Models to AI-driven Automated Optical Inspection
AMARO, Italy, July 4, 2024 /PRNewswire/ — Delvitech, a leader in 3D automated optical inspection for assembled printed circuit boards leveraging artificial intelligence, has joined forces with Eurotech, a global innovator in ultra-high-performance Edge AI Computers, to revolutionize quality control technology.
Delvitech’s patented integrated optical inspection technology, designed to collect comprehensive data to drive neural networks in optical inspection, gains crucial support from Eurotech’s hardware. This collaboration boosts the efficiency of assembling printed circuit boards, greatly increasing assembly machine uptime and significantly reducing waste and rework.
Employing the patented optical head, Delvitech captures detailed images that are processed through its software, adept at detecting assembly and welding errors in the electronics manufacturing process. Eurotech’s hardware complements this system by offering the speed and computational accuracy necessary to handle the massive influx of data required for the algorithms to produce desired outcomes.
This integrated 3D solution is highly competitive and flexible, allowing customization to meet specific customer needs. As board electronics become increasingly complex, Delvitech’s technology surpasses traditional mathematical models by analyzing a variety of components, such as metal parts, transparent glues, and silicone elements.
Moreover, this collaboration enables Delvitech and Eurotech to offer a solution that not only identifies errors but also drives AI models to detect deviations and trends, proactively preventing future errors and enhancing process quality.
“In an environment where quality control demands are continuously growing, it is crucial to develop optical inspection systems with optimal performance and partner with providers of state-of-the-art solutions. Eurotech offers highly reliable solutions, extensively tested to meet our high-performance requirements,” said Roberto Gatti, CEO of Delvitech.
Paul Chawla, CEO of Eurotech, added, “Our collaboration with Delvitech showcases the power of our Edge AI solutions. We empower our partners to deliver efficient, cost-effective, and scalable solutions where accuracy and speed are critical.”
Currently focusing on optical control of boards and soon semiconductors, the partnership aspires to expand into other sectors, including medical and food, with a strong emphasis on cybersecurity and sustainability.
As Delvitech and Eurotech continue to innovate, they bring unique strengths to the table. Delvitech commits to “less errors, less waste, less CO2, more future,” while Eurotech focuses on “more security, more resilience, more efficiency,” ensuring effective asset management and rapid scalability. These commitments reflect common shared goals of exceeding market and customer expectations today and in the future.
About Eurotech
Eurotech (ETH.IM) is a multinational company that designs, develops, and supplies Edge Computers and Internet of Things (IoT) solutions – complete with services, software and hardware – to system integrators and enterprises. By adopting Eurotech solutions, customers have access to IoT building blocks and software platforms, to Edge Gateways to enable asset monitoring, and to High Performance Edge Computers (HPEC) created for Artificial Intelligence (AI) applications. To offer increasingly comprehensive solutions,
Eurotech has partnered with leading companies in their field of action, with the view of creating “best in class” solutions for the Industrial Internet of Things.
Learn more
Contacts
Corporate Communication Federica Maion Tel. +39 0433 485411 [email protected]
About Delvitech
Delvitech is a Swiss based leading provider of AI-based automatic optical inspection (AOI) solutions aimed at revolutionizing the printed circuit board (PCB) assembly and electronics manufacturing landscape. With a focus on innovation and quality, Delvitech is capable of elevating both cost and process efficiencies, ensuring scalability and inspection repeatability on all production lines. It aspires to make the PCB production process swifter, more reliable, and highly scalable by not only detecting errors, but inspecting the whole production process. Delvitech solution is not just about minimizing errors; it is a commitment to reducing waste, cutting down CO2 emissions, and pioneering the path as the first sustainable AOI solution.
Contacts
Marketing DepartmentFederica RiosaTel. +41 916 460 [email protected]
Logo – https://mma.prnewswire.com/media/1897403/Eurotech_Logo.jpgLogo – https://mma.prnewswire.com/media/2453717/Delvitech_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/delvitech-and-eurotech-a-partnership-to-take-quality-control-to-the-next-level-302189001.html
-
Artificial Intelligence6 days agoSpotlight on Authentic AI: Developers Making Real Contributions Beyond AI Washing Claims
-
Artificial Intelligence6 days agoAsia Pacific View: Foreigners Looking for the Most Practical Smart Technology at the 2024 World Intelligence Expo
-
Artificial Intelligence6 days ago
CO2 AI Launches First Solution to Compute Product Emissions at Scale
-
Artificial Intelligence6 days agoLucinity’s AI Innovation Recognized at Microsoft’s Prestigious Global Partner Awards 2024
-
Artificial Intelligence6 days ago
Tech Companies Leading the Charge in the Transformative AI Era
-
Uncategorized7 days ago
Internal audit’s role in the new European Union’s Artificial Intelligence Act
-
Artificial Intelligence6 days ago
North American grocery retailer digitizes stores with Pricer Plaza in 90 MSEK order
-
Artificial Intelligence6 days agoHybrid Memory Cube Market Size to Grow USD 18651.2 Million by 2030 at a CAGR of 18.6% | Valuates Reports
